FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

Common Stock			09/17/2020		Month/Day/Year)	Code	v	Amount 19,289	<b>)</b> (1)	(A) or (D)	Price \$0.00	Owned Following Reported Transaction(s) (Instr. 3 and 4)		(I) (Instr. 4)	Ownership (Instr. 4)	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			Execution Date,		Transaction Disposed (Code (Instr. 5)		ties Acquired (A) or d Of (D) (Instr. 3, 4 a			and Securities Beneficially Owned Follo Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
4 770 - 60	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
(City)	(S	tate)	(Zip)										1 61301	1		
(Street) WALTH	AM M	ΙA	02451						Line	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
830 WINTER STREET				4. If Amendment, Date of Original Filed (Month/Day/Year)					6. In	6. Individual or Joint/Group Filing (Check Applicable						
(Last)	`	irst) APEUTICS, INC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/16/2020						)	below)	(give title See R	other below emarks	(specify	
Name and Address of Reporting Person*     Beskrovnaya Oxana				2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Dyne Therapeutics, Inc.</u> [ DYN ]						ck all applic Directo	cable) or		Owner			

## **Explanation of Responses:**

1. Consists of shares of Common Stock issuable under 19,289 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021.

Date

Exercisable

(2)

(D)

Expiration

09/15/2030

Title

Stock

2. This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024.

(A)

59,857

## Remarks:

Stock Option

(right to buy)

Senior Vice President, Head of Research

\$19

/s/ Richard Scalzo, Attorney-in-09/18/2020 **Fact** 

Amount or Number

Shares

59,857

\$0.00

59,857

D

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

09/16/2020

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.